Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a lab notebook—especially when Cellectar Biosciences packs pages with radioactive isotopes, orphan-drug milestones, and licensing clauses. If you have ever searched helplessly for trial costs or insider trades in its 10-K, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries turn Cellectar Biosciences SEC filings into plain-English insights. Need the Cellectar Biosciences quarterly earnings report 10-Q filing? It arrives the moment EDGAR posts, complete with an at-a-glance breakdown of cash runway, R&D spend, and pipeline updates. Curious about Cellectar Biosciences insider trading Form 4 transactions? Real-time alerts flag every executive move, so you no longer sift through PDFs.
Here’s what you’ll find on this page:
- Form 4 feeds that show Cellectar Biosciences Form 4 insider transactions real-time and highlight option grants before critical data readouts.
- AI commentary that makes sense of 8-Ks—think Cellectar Biosciences 8-K material events explained—so material trial results or FDA feedback never slip past you.
- Side-by-side redlines of the annual report—Cellectar Biosciences annual report 10-K simplified—pinpointing changes in liquidity, dilution risk, and collaboration revenue.
Whether you’re benchmarking R&D efficiency, tracking Cellectar Biosciences executive stock transactions Form 4, or performing a deep-dive Cellectar Biosciences earnings report filing analysis, our platform provides every filing type, updated in real time. Use AI to answer everyday questions like “understanding Cellectar Biosciences SEC documents with AI” or locating clauses on Cellectar Biosciences proxy statement executive compensation. Complex biotech disclosures become clear, so you can focus on decisions, not documents.
Cellectar Biosciences reports a mixed quarter: clinical progress on its lead radioconjugate and significant financial strain. Total assets declined to $13.7 million from $25.5 million, driven by a fall in cash and cash equivalents to $11.04 million from $23.29 million. The company recorded a net loss of $12.05 million for the six months and has an accumulated deficit of approximately $259.4 million. Operating expenses for the six months totaled $12.44 million, composed of research and development of $5.82 million and general and administrative of $6.62 million.
Operationally, Cellectar received Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom macroglobulinemia and reported strong CLOVER WaM results: a major response rate of 58.2% and an overall response rate of 83.6%. Development programs CLR 125 and CLR 225 are positioned for Phase 1 trials in 2025 but are explicitly conditioned on obtaining additional financing. Management discloses substantial doubt about going concern, with available liquidity near $15 million and runway described as limited absent further financing; planned actions include sales of equity/debt, strategic transactions, and cost savings. A July 2, 2025 underwritten offering raised approximately $6.9 million gross as a subsequent event.
Cellectar Biosciences, Inc. is reported to have Hexstone Capital LLC and Brendan O'Neil as joint reporting persons that beneficially own 150,000 shares of common stock, representing 5.6% of the outstanding shares used for this calculation. The percentage is calculated on a post-offering share count of 2,677,039 shares disclosed in the issuer's prospectus. Hexstone also holds 150,000 warrants exercisable for common stock, but those warrants are not included in the ownership total because they are subject to a 4.99% ownership limitation that blocks exercise if it would increase beneficial ownership above that threshold. Mr. O'Neil is the managing member of Hexstone and may be deemed to beneficially own the shares held by Hexstone; he does not directly own the shares. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Cellectar Biosciences (CLRB)?
What is the market cap of Cellectar Biosciences (CLRB)?
